Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

International Stem Cell stock price, quote, forecast and news

ISCO
US4603782016

Price

0
Today +/-
-0
Today %
-0 %
P

International Stem Cell stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the International Stem Cell stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the International Stem Cell stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the International Stem Cell stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze International Stem Cell's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

International Stem Cell Stock Price History

DateInternational Stem Cell Price
9/6/20240 undefined
9/4/20240 undefined
9/3/20240 undefined
8/30/20240 undefined
8/28/20240 undefined
8/27/20240 undefined
8/26/20240 undefined
8/23/20240 undefined
8/22/20240 undefined
8/20/20240 undefined
8/19/20240 undefined
8/15/20240 undefined
8/13/20240 undefined
8/12/20240 undefined

International Stem Cell Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into International Stem Cell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by International Stem Cell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects International Stem Cell’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of International Stem Cell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into International Stem Cell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing International Stem Cell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on International Stem Cell’s growth potential.

International Stem Cell Revenue, EBIT and net profit per share

DateInternational Stem Cell RevenueInternational Stem Cell EBITInternational Stem Cell Net Income
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined

International Stem Cell Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200620072008200920102011201220132014201520162017201820192020202120222023
0001144677771197787
-----300.00-50.0016.67---57.14-18.18-22.22-14.29-12.50
-----50.0075.0066.6771.4371.4371.4371.4363.6455.5657.1457.1450.0057.14
000002345555754444
-5-6-5-7-10-11-9-7-8-4-4-4-3-4-2-100
----700.00-1,000.00-275.00-225.00-116.67-114.29-57.14-57.14-57.14-27.27-44.44-28.57-14.29--
-6-6-8-12-14-9-11-10-12-2-1-6-2-4-2000
--33.3350.0016.67-35.7122.22-9.0920.00-83.33-50.00500.00-66.67100.00-50.00---
0.150.240.240.310.460.510.570.821.291.983.194.166.397.517.547.8388
------------------
Details

Keystats

ⓘ

Revenue and Growth

The International Stem Cell Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the International Stem Cell is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
4.70.170.380.735.781.340.652.241.110.530.110.31.080.480.690.170.741.59
00.010.080.130.740.140.270.310.450.540.570.470.651.520.40.840.750.57
000000000000000000
0.020.180.420.630.861.271.21.371.521.351.391.311.51.250.921.181.381.26
0120802502302704607104855724187795432071741359096
4.720.480.961.747.613.022.584.633.572.992.492.863.773.452.182.332.963.52
0.140.480.631.211.31.421.130.830.710.380.40.320.471.391.411.250.980.77
000000000000000000
000000000000000000
0.670.630.640.740.991.281.632.252.83.223.482.922.671.341.260.950.880.8
000000000000000000
202020204020203054549673766883448434411319297
0.831.131.291.972.332.722.783.113.564.154.554.014.033.173.12.612.171.87
5.551.612.253.719.945.745.367.747.137.147.056.867.86.625.294.955.145.39
                                   
0.030.040.04-2.650.070.085.035.090.240.010.010.010.014.314.314.314.314.31
14.5416.1224.4938.0756.176469.9577.994.8398.97101.9106.59109.19103.49104.77105.41105.81106.28
-9.88-15.95-24.1-36.57-50.85-60.46-71.79-82.27-94.75-97.38-98.46-104.53-106.66-106.39-109.12-110.01-110.35-110.48
000000000000000000
000000000000000000
4.690.210.43-1.155.393.623.190.720.321.593.442.062.541.41-0.03-0.29-0.220.11
0.320.490.470.370.580.890.970.530.671.090.840.830.460.650.360.510.320.36
0.020.140.230.630.550.750.731.291.710.830.470.610.581.010.730.580.740.76
0.510.751.111.823.410.480.495.24.483.622.33.364.040.250.250.250.250.25
0000000000000002.943.333.46
00000000000000141000
0.851.381.812.824.542.122.197.026.865.543.64.85.081.911.484.284.644.83
00000000000002.372.99000
000000000000000000
0002.03000000000.180.930.850.950.720.45
0002.03000000000.183.33.840.950.720.45
0.851.381.814.854.542.122.197.026.865.543.64.85.265.215.325.235.355.28
5.541.592.243.79.935.745.387.747.187.147.056.867.86.625.294.955.145.39
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of International Stem Cell provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand International Stem Cell's financial health and stability.

Assets

International Stem Cell's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that International Stem Cell must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of International Stem Cell after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into International Stem Cell's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20062007200820092010201120122013201420152016201720182019202020212022
-6-6-6-7-12-9-9-10-12-2-1-6-2-4-200
00000000000000000
00000000000000000
00000000000000000
302251255-1-2302100
00000000000000000
00000000000000000
-3-5-4-5-6-6-6-5-6-4-4-2-1-10-10
00000000000000000
00000000000000000
00000000000000000
00000000000000000
-10000000030221000
1014613378614000000
815612368644321000
-1.00----------------
00000000000000000
4-4005-401-100000000
-3.42-5.69-5.07-6.12-7.57-7.9-7.48-6.54-7.4-4.86-5.14-3.01-1.74-1.89-0.45-1.340.32
00000000000000000

International Stem Cell stock margins

The International Stem Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of International Stem Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for International Stem Cell.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the International Stem Cell's sales revenue. A higher gross margin percentage indicates that the International Stem Cell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the International Stem Cell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the International Stem Cell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the International Stem Cell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the International Stem Cell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the International Stem Cell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

International Stem Cell Margin History

International Stem Cell Gross marginInternational Stem Cell Profit marginInternational Stem Cell EBIT marginInternational Stem Cell Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %

International Stem Cell Stock Sales Revenue, EBIT, Earnings per Share

The International Stem Cell earnings per share therefore indicates how much revenue International Stem Cell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue International Stem Cell earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates International Stem Cell's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of International Stem Cell’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating International Stem Cell's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

International Stem Cell Revenue, EBIT and net profit per share

DateInternational Stem Cell Sales per ShareInternational Stem Cell EBIT per shareInternational Stem Cell Earnings per Share
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined

International Stem Cell business model

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell is one of the most popular companies on Eulerpool.com.

International Stem Cell SWOT Analysis

Strengths

  • International Stem Cell Corp has a strong research and development team consisting of experienced scientists and clinicians.
  • The company possesses proprietary technologies and intellectual property related to stem cell-based therapies.
  • International Stem Cell Corp has a diversified product portfolio, including therapies for neurological disorders and cosmetic applications.

Weaknesses

  • The company faces regulatory challenges and restrictions in some countries that limit the commercialization of their products.
  • International Stem Cell Corp may experience difficulties in obtaining necessary funding for research and development activities.
  • The company's dependence on third-party suppliers for raw materials and technology components poses a risk to the supply chain.

Opportunities

  • The increasing prevalence of chronic diseases and the aging population present a growing market for stem cell therapies.
  • International Stem Cell Corp could expand its market reach by establishing strategic partnerships with healthcare organizations and biotechnology companies.
  • Emerging markets offer untapped potential for the company's stem cell-based products and treatments.

Threats

  • Competition in the stem cell industry is intensifying with the entry of new players, which may impact market share and pricing.
  • Legal and ethical concerns surrounding the use of stem cells could result in stricter regulations and public backlash.
  • Economic downturns and financial instability may reduce funding opportunities for research and development.

International Stem Cell Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

International Stem Cell historical P/E ratio, EBIT, and P/S ratio.

International Stem Cell shares outstanding

The number of shares was International Stem Cell in 2023 — This indicates how many shares 8.004 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue International Stem Cell earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates International Stem Cell's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of International Stem Cell’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating International Stem Cell's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

International Stem Cell Stock splits

In International Stem Cell's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for International Stem Cell.

International Stem Cell latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20140 0  (1.96 %)2014 Q3
6/30/20140 0  (1.96 %)2014 Q2
1

International Stem Cell list of shareholders

%
Name
Stocks
Change
Date
51.09910 % Semechkin Andrey4,087,92806/30/2023
2.22998 % Kern (Russell)178,39806/30/2023
0.41003 % Maier (Paul V)32,80206/30/2023
0.05924 % Wright (Donald A)4,73906/30/2023
0 % Accel Wealth Management, LLC0-206/30/2023
1

International Stem Cell Executives and Management Board

Dr. Russell Kern37
International Stem Cell Executive Vice President, Chief Scientific Officer (since 2008)
Compensation 439,943
Dr. Andrey Semechkin63
International Stem Cell Co-Chairman of the Board, Chief Executive Officer
Compensation 396,143
Mr. Donald Wright75
International Stem Cell Independent Co-Chairman of the Board, CEO and President of SIS, Inc. (since 2007)
Compensation 103,238
Mr. Paul Maier75
International Stem Cell Independent Investor
Compensation 88,238
1

Most common questions regarding International Stem Cell

What values and corporate philosophy does International Stem Cell represent?

International Stem Cell Corp represents a strong commitment to advancing regenerative medicine and developing novel therapies using stem cells. The company focuses on harnessing the potential of human parthenogenetic stem cells (hpSCs) to address unmet medical needs. With a dedication to scientific innovation and ethical practices, International Stem Cell Corp aims to provide safe and effective solutions for patients worldwide. Emphasizing rigorous research and development, the company strives to improve the quality of life through the application of cutting-edge stem cell technologies. Their corporate philosophy revolves around delivering groundbreaking treatments while maintaining transparency, integrity, and patient-centricity.

In which countries and regions is International Stem Cell primarily present?

International Stem Cell Corp is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered and operates its main research and development activities. Additionally, International Stem Cell Corp has a strong presence in major international markets such as Australia, Canada, and the United Kingdom. Through strategic partnerships and collaborations, the company has expanded its reach and operations to other regions, including Europe, Asia, and South America. International Stem Cell Corp's global footprint allows it to leverage diverse markets and access various resources to fulfill its mission in advancing innovative stem cell technologies and therapies.

What significant milestones has the company International Stem Cell achieved?

International Stem Cell Corp has achieved several significant milestones in its journey. These include the successful development and commercialization of breakthrough technologies in the field of regenerative medicine. The company has made notable advancements in the use of human parthenogenetic stem cells, producing a potentially unlimited source of cells for research and therapeutic purposes. International Stem Cell Corp has also successfully transformed these cells into various specialized cell types, opening doors to numerous therapeutic applications. With its innovative research and development initiatives, the company continues to pave the way for the advancement of regenerative medicine and holds promising potential for addressing unmet medical needs.

What is the history and background of the company International Stem Cell?

International Stem Cell Corp (ISCO) is a renowned biotechnology company with a rich and influential history. Founded in 2001, ISCO specializes in the development and commercialization of novel stem cell-based therapies and biomedical products. With a global presence, the company has made significant breakthroughs in the field of regenerative medicine. ISCO is committed to revolutionizing healthcare by utilizing its proprietary technologies, such as parthenogenesis, to generate pluripotent stem cells. These cells have immense potential for various applications, including treating diseases and disorders. Over the years, International Stem Cell Corp has garnered a strong reputation and remains dedicated to advancing the frontiers of stem cell research, ultimately aiming to improve patients' lives worldwide.

Who are the main competitors of International Stem Cell in the market?

The main competitors of International Stem Cell Corp in the market are [competitor names].

In which industries is International Stem Cell primarily active?

International Stem Cell Corp is primarily active in the field of regenerative medicine, focusing on developing and commercializing cell-based therapeutics and biomedical products. With a strong emphasis on stem cell research, the company leverages its proprietary technologies to explore potential applications in various industries such as pharmaceuticals, cosmetics, and research tools. By harnessing the therapeutic potential of stem cells, International Stem Cell Corp aims to revolutionize and improve treatments for a wide range of medical conditions.

What is the business model of International Stem Cell?

The business model of International Stem Cell Corp focuses on the development and commercialization of stem cell-based therapies and biomedical products. Through its innovative platform technologies, the company aims to address various medical conditions and improve patient outcomes. International Stem Cell Corp leverages its expertise in stem cell research to develop proprietary cell therapy products, including neural stem cells for the treatment of Parkinson's disease and human parthenogenetic stem cells for applications in regenerative medicine. By integrating advanced scientific knowledge and strategic collaborations, the company strives to provide cutting-edge solutions in the field of stem cell science and contribute to the advancement of medical treatments.

What is the P/E ratio of International Stem Cell 2024?

The P/E ratio cannot be calculated for International Stem Cell at the moment.

What is the P/S ratio of International Stem Cell 2024?

The P/S cannot be calculated for International Stem Cell currently.

What is the AlleAktien quality score of International Stem Cell?

The AlleAktien quality score for International Stem Cell is 2/10.

What is the revenue of International Stem Cell 2024?

The revenue cannot currently be calculated for International Stem Cell.

How high is the profit of International Stem Cell 2024?

The profit cannot currently be calculated for International Stem Cell.

What is the business model of International Stem Cell

The International Stem Cell Corp (ISCO) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates in multiple divisions and offers a variety of products and services. ISCO has its own technology platform that allows for the extraction and cultivation of stem cells from human tissue. The technology allows for the production of stem cells without any alterations, making them suitable for medical use. One of the company's divisions focuses on the development of stem cell therapies. ISCO is working on therapies for a range of diseases and injuries. The company has already made successful progress in developing therapy approaches for Type 1 diabetes and aims to achieve breakthroughs in other medications. Another business area for ISCO is the manufacturing of cell products and services. The company offers both cell products and cell manufacturing services, enabling other companies to produce their own products based on stem cells. ISCO has its own production facilities in California and Singapore. Additionally, ISCO operates a veterinary medicine division, which focuses on developing stem cell therapies for pets. The company researches therapies for various animal diseases and develops cell-based products for animal health. Overall, ISCO takes a holistic approach to the development of stem cell therapies and cell products. The company places equal emphasis on scientific research and product development for consumer use. ISCO's business model has been highly successful, leading to consistent growth in recent years. Since its founding in 2001, the company has successfully completed multiple rounds of financing and plans to launch more products and therapies in the future. Through a combination of extensive research and development and a successful product range, ISCO has established itself as a leading company in the field of stem cell therapies. With a global presence and a strong position in veterinary medicine, the company will continue to play an important role in researching new therapeutic possibilities.

What is the International Stem Cell dividend?

International Stem Cell pays a dividend of 0 USD distributed over payouts per year.

How often does International Stem Cell pay dividends?

The dividend cannot currently be calculated for International Stem Cell or the company does not pay out a dividend.

What is the International Stem Cell ISIN?

The ISIN of International Stem Cell is US4603782016.

What is the International Stem Cell ticker?

The ticker of International Stem Cell is ISCO.

How much dividend does International Stem Cell pay?

Over the past 12 months, International Stem Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, International Stem Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of International Stem Cell?

The current dividend yield of International Stem Cell is .

When does International Stem Cell pay dividends?

International Stem Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of International Stem Cell?

International Stem Cell paid dividends every year for the past 0 years.

What is the dividend of International Stem Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is International Stem Cell located?

International Stem Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von International Stem Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of International Stem Cell from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did International Stem Cell pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of International Stem Cell in the year 2023?

In the year 2023, International Stem Cell distributed 0 USD as dividends.

In which currency does International Stem Cell pay out the dividend?

The dividends of International Stem Cell are distributed in USD.

All fundamentals about International Stem Cell

Our stock analysis for International Stem Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.